Secretory phospholipase A$_2$ as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids

Simon S. Jensen,[1] Thomas L. Andresen,[1,2] Jesper Davidsen,[1] Pernille Høyrup,[1] Steven D. Shnyder,[3] Michael C. Bibby,[3] Jason H. Gill,[3] and Kent Jørgensen[1]

[1]LiPlasome Pharma A/S and [2]Department of Chemistry, Technical University of Denmark, Lyngby, Denmark and [3]Cancer Research Unit, Tom Connors Cancer Research Centre, University of Bradford, Bradford, United Kingdom

Abstract

The use of many common clinically relevant chemotherapeutics is often limited due to insufficient delivery to the tumor and dose-limiting systemic toxicities. Therefore, therapeutics that specifically target tumor cells and are nontoxic to normal cells are required. Here, we report the development of a novel class of liposomes composed of lipid prodrugs, which use the increased secretory phospholipase A$_2$ type IIA (sPLA$_2$) activity of the tumor microenvironment as a trigger for the release of anticancer etherlipids (AEL). Treatment of sPLA$_2$-secreting tumor cells *in vitro* with liposomes consisting of proAELs resulted in growth inhibition comparable with addition of the AELs alone. Using a specific sPLA$_2$ inhibitor, we showed the low cytotoxicity of the non-hydrolyzed proAEL liposomes and have proven the sPLA$_2$ dependency of the activation of proAELs to cytotoxic AELs. In addition, we showed that our proAEL liposomes circumvent the inherent hemolytic toxicities associated with the use of etherlipids, thereby allowing i.v. administration of such therapeutics as nontoxic prodrug liposomes. Furthermore, using a sPLA$_2$-secreting human colon cancer xenograft model, we showed that the proAEL liposomes are capable of inducing a tumor growth delay *in vivo*. Taken together, these data support the validity of this novel tumor-selective liposomal prodrug delivery strategy. This new approach also provides a promising system for tumor-selective delivery and release of conventional chemotherapeutics encapsulated in the sPLA$_2$-degradable prodrug liposomes. [Mol Cancer Ther 2004;3(11):1451–8]

Introduction

One of the major goals of modern medicine is the identification and development of more effective tumor-selective anticancer treatments. Although many chemotherapeutics are highly potent in laboratory-based cell studies, their clinical usage is limited as a result of inadequate delivery of therapeutic doses to the tumor or harmful effects on normal organ function. To circumvent these limitations and lower the systemic side effects, novel targeted microcarrier technologies involving tumor-specific drug delivery and activation are clearly required. Several such approaches for targeting of therapeutics specifically to malignant tissue have been described including antibody-directed prodrug therapy (1), protease-activated prodrug and liposomal drug delivery (2–6), and mild hyperthermia-mediated liposomal drug release (7).

In this article, we report a new tumor-selective prodrug delivery strategy in which tumor enzymology is used as a site-specific trigger (8) for activation of a new generation of liposomes composed of prodrug anticancer lipids. This liposomal prodrug system has the advantage that in addition to tumor-selective prodrug activation and release it can also be used as a microcarrier system for many anticancer therapeutics including radiation sensitizers, cytokines, immunomodulators, or conventional chemotherapeutics such as the anthracyclines, platins, camptothecins, or topoisomerase inhibitors (8, 9).

Enzymes used to activate prodrugs in tumors must fulfil two criteria: (*a*) significantly higher expression and activity in tumor tissue compared with normal tissues and (*b*) a substrate specificity amenable to the development of prodrugs. One class of enzyme that satisfies these requirements are the phospholipase A$_2$ (PLA$_2$) family, specifically secretory PLA$_2$ type IIA (sPLA$_2$). Unlike other PLA$_2$ family members, sPLA$_2$ is released into the extracellular matrix where it associates with the cell surface and induces fatty acid release for downstream prostaglandin synthesis (10–13). Elevated expression of sPLA$_2$ has been shown in several human tumor types including breast, gastric, pancreatic, prostate, small bowel, and colon (10, 11, 13–20). In addition, sPLA$_2$ levels have also been shown to be significantly higher during tumor vascularization (21) and in tumors that show distant metastasis (11). With reference to its substrate specificity, sPLA$_2$ is an interfacially activated lipase that has a preference for organized

lipid substrates (such as liposomes) compared with mono-meric lipids in solution (22–24), supporting the use of sPLA$_2$ as a tumor-specific trigger for liposomal prodrug activation.

Anticancer etherlipids (AEL) belong to a potent class of drug, which can inhibit tumor cell growth without causing mutagenic or myelosuppressive effects (25–27). Unfortunately, AELs have been shown to be severely hemolytic *in vivo*, thereby prohibiting their i.v. administration at therapeutic concentrations (25–27) and limiting their clinical use (27, 28). To circumvent the hemolytic effects of AELs, several strategies have been used previously including p.o., i.p., and topical administration as well as incorporation of a minor fraction of the AELs into stable liposomes (29–31). Our strategy involves the design and synthesis of novel prodrug lipids (proAEL), which can be used to make prodrug liposomes creating both a sPLA$_2$-dependent anticancer prodrug and a drug delivery system (Fig. 1). This integrated concept would allow for transport of high concentrations of the nontoxic proAEL liposomes to the tumor where the proAELs subsequently would undergo a site-specific sPLA$_2$-mediated activation to AELs and induce tumor cell cytotoxicity.

In this study, we describe the rational design and development of these proAEL liposomes, their specific activation by sPLA$_2$, their cytotoxicity against sPLA$_2$-secreting human tumor cell lines, and their potential use as a new promising tumor-activated prodrug delivery system.

Materials and Methods

Synthesis of proAEL and AEL

ProAELs were synthesized using a short enantiopure strategy using (*R*)-*O*-benzyl glycidol as the chiral starting material (32, 33). Regioselective opening of the epoxide followed by acylation and deprotection resulted in 1-*O*-hexadecyl-2-hexadecanoyl-*sn*-glycerol, which immediately

Figure 1. General overview of our sPLA$_2$-dependent liposomal prodrug concept. Polymer-covered liposomes consisting of lipid prodrugs (proAELs) of AELs are stable in the bloodstream. Due to the leaky vasculature and elevated levels of sPLA$_2$ in tumors, the long circulating proAEL liposomes accumulate in the malignant tissue, where they are converted to active AELs. In this way, the triggered release of the active AELs becomes site specific to the desired target tumor site.

Figure 2. Synthesis and chemical structures of the proAEL-PC and proAEL-PG liposome components. Main steps involved in *de novo* synthesis of proAEL-PC and proAEL-PG from (*R*)-*O*-benzyl glycidol. Reagents: (*a*) C$_{16}$H$_{33}$OH, NaH, THF/DMF 1:1, 80°C; (*b*) C$_{15}$H$_{31}$COOH, DCC, DMAP, CH$_2$Cl$_2$ (70% two steps); (*c*) H$_2$, Pd/C, EtOAc (100%); (*d*) (i. POCl$_3$, Et$_3$N, CH$_2$Cl$_2$), [ii. choline tosylate, pyridine] (78%); (*e*) (i. MeOPOCl$_2$, TMP, toluene], [ii. L-α,β-isopropylideneglycerol, TMP] (77%); (*f*) NaI, 2-butanone, 70°C; (*g*) CF$_3$COOH, CH$_2$Cl$_2$, methanol, 0°C (71% two steps).

was phosphorylated using POCl$_3$ and choline tosylate, resulting in 1-*O*-hexadecyl-2-hexadecanoyl-*sn*-glycero-3-phosphocholine (proAEL-PC). (*S*)-1-*O*-hexadecyl-2-hexa-decanoyl-*sn*-glycero-3-phosphoglycerol (proAEL-PG) was synthesized using methyl dichlorophosphate followed by deprotection. (*S*)-1-*O*-hexadecyl-2-hydroxy-*sn*-glycero-3-phosphoglycerol (AEL-PG) and 1-*O*-hexadecyl-2-hydroxy-*sn*-glycero-3-phosphocholine (AEL-PC) were synthesized using the same conditions but with 1-*O*-hexadecyl-2-*O*-benzyl-*sn*-glycerol as the chiral starting material. The synthesis is briefly depicted in Fig. 2.

Preparation of proAEL Liposomes

ProAEL liposomes were prepared by hydration of proAELs in water and sonicated for 14 minutes using a probe sonicator to give small unilamellar proAEL liposomes (<100 nm). Pegylation of liposomes was done using PE-PEG2000 (di-octadecanoyl-*sn*-glycero-3-phosphoetha-nolamine-*N*-[methoxy-(polyethylene glycol)2000]; Avanti Polar Lipids, Alabaster, AL).

Hydrolysis of proAEL Liposomes by sPLA$_2$

The concentration and degree of hydrolysis of the proAEL liposomes was quantitated using high-performance liquid chromatography (32). ProAEL liposomes (0.3 mmol/L) were incubated with sPLA$_2$ (100 ng/mL) derived from human tear fluid as described previously (34). All samples were dissolved in chloroform/ethanol/water/acetic acid (4:8:1:1 v/v) and desalted by extraction with water. High-performance liquid chromatography analysis was done using an eluent mixture of chloroform/metha-nol/water (73:23:3 v/v), a 5 μm spherical diol column, and an evaporative light scattering detector.

Cell Culture and Measurement of sPLA$_2$ Secretion

The KATO III human gastric carcinoma cell line was purchased from the Japan Health Sciences Foundation (Tokyo, Japan). The COLO 205 human colon carcinoma cell line and human umbilical vein endothelial cells (HUVEC) were purchased from European Collection of Animal Cell Cultures (Salisbury, United Kingdom) and American Type Culture Collection (Manassas, VA), respectively. KATO III

and COLO 205 cells were grown in RPMI 1640 supplemented with 10% heat-inactivated FCS, L-glutamine (2 mmol/L), and sodium pyruvate (1 mmol/L) in a humidified 5% CO_2 atmosphere at 37°C. HUVECs were grown in Ham's F-12 medium supplemented with 10% FCS, L-glutamine (2 mmol/L), heparin (0.1 mg/mL), and endothelial cell growth supplement (50 ng/mL, Sigma, Poole, United Kingdom). Following 72 hours of growth, cell growth medium and cell pellets were collected. Quantitation of $sPLA_2$ protein was determined by a human-specific $sPLA_2$ ELISA assay according to manufacturer's instructions (Cayman Chemical, Ann Arbor, MI). All studies were done in triplicate.

In vitro Determination of Cytotoxicity

Cells (KATO III and COLO 205) were plated in 96-well plates at a density of 1×10^4 cells per well in RPMI 1640. After overnight incubation to allow for cell attachment, the medium was removed and replaced with fresh medium containing varying concentrations of AELs (10–200 μmol/L) and proAEL liposomes (50–200 μmol/L) and the cells were further incubated for 72 hours at 37°C. To study $sPLA_2$ specificity, the specific $sPLA_2$ inhibitor LY311727 (kindly provided by Eli Lilly & Co., Indianapolis, IN) was added 10 minutes prior to the proAEL liposomes at a concentration of 25 μmol/L. To verify efficient proAEL hydrolysis, $sPLA_2$ from human tear fluid was added to the cells at a concentration of 100 ng/mL. Chemosensitivity was assessed using a standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (35). Values for cell survival are expressed as the percentage reduction in cell numbers relative to the solvent controls. All studies were done in triplicate.

Expression of $sPLA_2$ in COLO 205 Xenograft

Localization of $sPLA_2$ was assessed by immunohistochemistry in paraffin-embedded 5 μm sections of COLO 205 human colon tumor xenograft. Briefly, sections were dewaxed in xylene and rehydrated to water through graded alcohols. Heat-mediated antigen retrieval was done by microwaving the slides in citric acid buffer (0.01 mol/L, pH 6.0). Endogenous peroxidase activity was quenched with freshly prepared 1% hydrogen peroxide. Nonspecific antibody binding was inhibited using 5% normal horse serum. Sections were then incubated overnight at 4°C in a humidified atmosphere with the primary monoclonal antibody raised against $sPLA_2$ (Cayman Chemical) diluted 1:20 in PBS. Negative staining controls were done using normal mouse IgG (DAKO, Cambridge, United Kingdom) in place of the primary antibody. After washing in PBS, sections were incubated for 30 minutes at room temperature with an anti-mouse biotinylated secondary antibody (Vector Laboratories, Burlingame, CA) followed by amplification and detection using a Vectastain ABC kit according to the manufacturer's instructions (Vector Laboratories). Immunocomplex visualization was done using 3,3′-diaminobenzidine according to the manufacturer's instructions (Vector Laboratories). Sections were counterstained with Harris' hematoxylin and mounted in DPX mountant (Sigma).

Hemolysis Assay

Human RBC (4% in PBS) were incubated with AEL or proAEL liposomes (0.5 mL, 1 mmol/L) for 1 hour at 37°C with constant rotation. The suspension was centrifuged ($2,000 \times g$) and the level of free hemoglobin was measured spectrophotometrically at 550 nm. RBC (4%) in PBS served as a negative control. Total hemolysis was defined as that obtained after incubation of RBC with 1% Triton X-100. The $ET-18-OCH_3$ etherlipid, edelfosine (Avanti Polar Lipids), was used as a control.

Effect of proAEL Liposomes in the COLO 205 Xenograft Model

Female mice (*nu/nu* from an inbred colony, B&K Universal, Hull, United Kingdom) 6 to 8 weeks old were implanted s.c. with 2 to 3 mm^3 fragments of COLO 205 tumor. Once tumors could be accurately measured, mice were allocated into groups of six by restricted randomization to keep group mean tumor size variation to a minimum. Mice were given i.p. injections of vehicle or proAEL liposomes [300 mg/kg; proAEL-PC/proAEL-PG/PE-PEG2000 (20:70:10 mol %)] on days 0, 1, 2, 3, 4, 7, 8, 9, 10, and 11 (the initial day of therapy being designated day 0). Tumor size and body weight of each mouse were monitored daily thereafter. Tumor volume was determined using the formula: $(a^2 \times b) / 2$, where a is the smaller and b the larger dimension of the tumor. Tumor volume was then normalized to the respective volume on day 0, and semilog plots of relative tumor volume versus time were made. Maximum tumor inhibition (% treated versus control) was calculated by the formula: $100 \times$ [Relative tumor volume (treated animals)] / [Relative tumor volume (control animals)]. Mann-Whitney U tests were done to determine the statistical significance of any differences in growth rate (based on tumor volume doubling time: 8.5 days for control and 12.0 days for proAEL liposomes) between control and treated groups. All procedures in this phase of the study were carried out under a project license issued by the UK Home Office, and UK Coordinating Committee on Cancer Research guidelines were followed.

Results

Specificity of $sPLA_2$ toward proAEL Liposomes

Hydrolysis of the proAEL liposomes by $sPLA_2$ was monitored over time using high-performance liquid chromatography. The level of proAEL hydrolysis was calculated on basis of the integrated area before and after addition of $sPLA_2$. Following 24 hours of incubation of proAEL liposomes composed of proAEL-PG or proAEL-PC (with $sPLA_2$), ~60% of the proAEL-PG lipids were hydrolyzed and <10% of the proAEL-PC liposomes were hydrolyzed (Fig. 3A and B). This is in agreement with previous studies suggesting a preference of $sPLA_2$ for anionic lipid substrates (PG) over zwitterionic lipids (PC; refs. 24, 34). Incorporation of small amounts of polymer lipids (5 mol % PE-PEG2000) into the anionic proAEL-PG liposomes, which is necessary to avoid the clearance by the reticuloendothelial system in the bloodstream (36), did not

Figure 3. sPLA₂-catalyzed hydrolysis at 37°C of proAEL liposomes composed of (**A**) proAEL-PC (100 mol %), (**B**) proAEL-PG (100 mol %), and (**C**) proAEL-PG/PE-PEG2000 (95:5 mol %). The high-performance liquid chromatography chromatograms show the amount of proAEL lipids before sPLA₂ was added (*solid lines*) and the amount of unhydrolyzed lipids following 30-minute incubation (*dashed lines*) and 24-hour incubation (*fine dashed lines*) with sPLA₂. The concentration of the proAEL liposomes was 300 nmol/L and sPLA₂ was 100 ng/mL in each case.

inhibit the sPLA₂-catalyzed hydrolysis of the proAEL-PG lipids (Fig. 3C). This is consistent with earlier hydrolysis studies showing that the steric barrier induced by the polymer coverage does not prevent the small lipolytic sPLA₂ enzyme (14 kDa) from reaching the liposomal surface, where the interfacial lipid hydrolysis occurs (8, 32).

Secretion of sPLA₂ by Human Tumor Cell Lines

Levels of sPLA₂ were evaluated and measured in the growth medium of human KATO III and COLO 205 epithelial tumor cell lines and normal endothelial cells (HUVEC). The amount of sPLA₂ secreted from the KATO III and COLO 205 tumor cell lines into the growth medium following 72 hours of *in vitro* culture was 3 ± 1.7 and 75 ± 20 ng/mL sPLA₂, respectively. In contrast, sPLA₂ was undetectable (<15 pg/mL) in medium from HUVECs.

In vitro Toxicity of AELs and proAELs

The cytotoxic effect of AEL-PG and AEL-PC and their corresponding prodrug liposomal formulations (proAEL-PG and proAEL-PC) were assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and the concentration capable of inhibiting cell growth by 50% (IC₅₀) was determined for each compound in each cell line. The AELs showed cytotoxic activity against both KATO III and COLO 205, with IC₅₀ values in the 50 to 200 μmol/L range. Exposure of COLO 205 and KATO III cells to proAEL-PG/PE-PEG2000 liposomes (95:5 mol %) for 72 hours resulted in a dose-dependent cytotoxic activity, with IC₅₀ values similar to treatment with the free AELs (Fig. 4A). In accordance with the substrate specificity of sPLA₂ reported in Fig. 3, proAEL-PC liposomes did not induce growth inhibition in any cell type tested (data not shown). Addition of sPLA₂ (~100 ng/mL) to KATO III or COLO 205 cells treated with the proAEL-PG/PE-PEG2000

Figure 4. Cytotoxicity of proAEL liposomes composed of proAEL-PG/PE-PEG2000 (95:5 mol %) against (**A**) sPLA₂-secreting COLO 205 (*hatched columns*) and KATO III (*solid columns*). The inhibition of cytotoxicity by coaddition of the sPLA₂ inhibitor, LY311727, shows the dependence of the effect on sPLA₂ activity. Efficient proAEL liposome hydrolysis is shown by the lack of further activity following administration of exogenous sPLA₂. **B,** lack of proAEL liposome-mediated cytotoxicity against the non-sPLA₂-secreting HUVEC cells further reinforced the specificity of the proAEL concept toward sPLA₂. All studies were done in triplicate.

liposomes only marginally increased growth inhibition, indicating rapid and almost complete proAEL-PG hydrolysis by $sPLA_2$ secreted by the cell lines (Fig. 4A). Addition of the specific $sPLA_2$ inhibitor, LY311727, 10 minutes prior to addition of the proAEL liposomes resulted in a lack of cytotoxic activity, supporting a dependence of the proAEL hydrolysis and cytotoxic etherlipid generation on $sPLA_2$ activity (Fig. 4A). In contrast, no growth inhibition was observed in the non-$sPLA_2$-secreting HUVEC cells following exposure to proAEL-PG liposomes for 72 hours (Fig. 4B).

### Lack of Hemolytic Effects of proAEL Liposomes Compared with Free AELs

Hemolysis is the major limiting factor to the use of AELs *in vivo*. In the *in vitro* assay, both AEL-PC and AEL-PG showed hemolytic activity comparable with that observed by the potent edelfosine etherlipid (Fig. 5). In contrast, no significant hemolysis was observed in the presence of any of the proAEL liposomes (Fig. 5). These data are further supported by a lack of systemic toxicity following i.v. administration of >300 mg/kg of the proAEL liposomes in the mouse studies.

Lack of Systemic *In vivo* Toxicity by proAEL Liposomes

Because AELs have been shown previously to cause severe toxicity *in vivo*, we attempted to determine the max-

Figure 6. $sPLA_2$ protein is expressed in COLO 205 xenografts. Immunohistochemistry showed highest expression of $sPLA_2$ protein at the tumor periphery (*P*). Bar, 300 μm.

imum tolerated dose for the proAEL liposomes prior to commencing antitumor studies. No systemic toxicity was observed in non-tumor-bearing mice even at i.p. doses of 1,000 mg/kg proAEL liposomes (proAEL-PC/proAEL-PG/PE-PEG2000, 20:70:10 mol %). No significant body weight loss was observed in any of these mice (data not shown).

Growth Inhibition by proAEL Liposomes in the COLO 205 Xenograft Model

Because the proAEL liposomes showed promise *in vitro*, we examined the potential antitumor activity *in vivo* against s.c. implanted $sPLA_2$-secreting COLO 205 human colon adenocarcinoma xenografts in nude mice. Immunohistochemical analyses of COLO 205 xenograft tumors confirmed the continued expression of $sPLA_2$ *in vivo*, with highest $sPLA_2$ expression being observed at the tumor periphery (Fig. 6). I.p. injection of proAEL liposomes resulted in a statistically significant tumor growth delay (3.4 days) with a maximum tumor inhibition on day 4 at 67.9% compared with controls. Although a slight reduction in mouse body weight 1 day post-commencement of treatment was observed in both control group (2.8% weight loss) and treated group (5.1% weight loss), all mice returned to their starting weight within a few days and continued to gain weight ($P < 0.01$), suggesting minimal toxic effects.

Discussion

The clinical use of many chemotherapeutics is often limited by a combination of poor delivery to the tumor and dose-limiting side effects on normal tissue function. To overcome these limitations, increased tumor selectivity and efficacy can be achieved by using nontoxic prodrugs that are converted to the active parent drugs at the target tumor site. ProAEL liposomes are a new generation of prodrug liposomal carriers that can be used for targeted transport and delivery of etherlipids to malignant tissue. Activation of the proAEL liposomes to AELs is triggered by $sPLA_2$,

Figure 5. Hemolysis of AEL-PC, AEL-PG, and ET-18-OCH₃ etherlipids and proAEL liposomes composed of proAEL-PC (100 mol %), proAEL-PG (100 mol %), and proAEL-PG/PE-PEG2000 (95:5 mol %). Both AEL-PC and AEL-PG induce hemolysis to a similar level as the potent etherlipid, edelfosine (ET-18-OCH₃), following incubation at 1 mmol/L for 1 hour with human RBC. In contrast, very low levels of hemolysis are observed with the prodrug liposomes composed of proAEL-PC, proAEL-PG, or proAEL-PG/PE-PEG2000. All results are expressed in relation to 100% hemolysis observed in the presence of Triton X-100.

which is highly expressed and active in tumor tissue. As such, proAEL liposomes avoid the systemic toxicity problems related to many chemotherapeutics by allowing delivery of high doses of proAEL liposomes to tumors where the proAELs subsequently become activated to AELs by overexpressed sPLA₂.

Although both AEL-PG and AEL-PC showed similar levels of cellular toxicity, differential toxicities were observed when the proAELs of these etherlipids were investigated as prodrug liposomes. Whereas the negatively charged proAEL-PG liposomes inhibited *in vitro* growth of sPLA₂-secreting cells comparable with AEL-PG, the zwitterionic proAEL-PC liposomes did not inhibit growth of these cells. This differential substrate specificity of sPLA₂, as reported previously (24, 34), is of particular importance to our approach, as it shows that sPLA₂ present at the tumor site acts preferentially on the anionic prodrug liposomes. Furthermore, it offers a rational way to tailor the degradation profile of the prodrug liposomes by sPLA₂ at the tumor target site. The relevant degradation time refers to a dynamic process that is determined by the accumulation and residence time of the prodrug liposomes in the tumor and the amount of secreted and active sPLA₂ in the extracellular environment of the tumor tissue. These variables are presently unknown but need to be explored in future biodistribution and pharmacokinetic studies to control and optimize the degradability of the proAEL liposomes by sPLA₂ in the tumor tissue. It should however be pointed out that a high degree of proAEL-PC hydrolysis is achievable (data not shown) if the anionic proAEL-PG lipids compose a major part (>60 mol %) of the liposomal membrane. By adjusting the proAEL-PG/proAEL-PC composition and the surface properties of the liposomal prodrug substrate, it is therefore possible in future studies to fine-tune and optimize the liposomal sPLA₂ lability at the tumor target site to regulate the tumor-specific drug release, suggested recently by Allen and Cullis (36) as a crucial variable for future liposome-based drug delivery. Pegylation of the liposomes, which is required to avoid reticuloendothelial clearance and promote blood circulation and passive accumulation in the tumor (37), did not inhibit the interfacial sPLA₂-mediated hydrolysis of the proAEL liposomes, thereby supporting the pharmacokinetic and pharmacodynamic profile of our approach.

Tumor specificity of the new prodrug concept is provided by the dependence of proAEL liposomal cleavage on sPLA₂. This is supported by cytotoxicity against sPLA₂-secreting cell lines, COLO 205 and KATO III, compared with a lack of significant response in non-sPLA₂-secreting HUVEC cells. Furthermore, inclusion of a sPLA₂-specific inhibitor prevented proAEL-PG-mediated cytotoxicity of sPLA₂-secreting cells *in vitro*, reinforcing the requirement for sPLA₂. Addition of exogenous sPLA₂ to the culture system did not significantly increase growth inhibition, suggesting complete and rapid AEL generation by sPLA₂ secreted from the cancer cells.

Etherlipids have been shown previously to inhibit tumor cell growth without causing mutagenic or myelosuppressive effects (25–27). Their epigenetic mode of action involves incorporation into cellular membranes, resulting in perturbation of key membrane-associated processes and disruption of normal cell function (25–27). With reference to their use as anticancer agents, these effects include cell cycle arrest, inhibition of invasion and differentiation, induction of apoptosis, and ultimately cell death (27, 28). The major disadvantage to the use of AELs therapeutically is their inherent toxicity against RBC *in vivo* and subsequent limited use as antitumor therapeutics (27, 28). Consequently, these effects prohibit i.v. administration of AELs at therapeutic concentrations (25–27) and limit their clinical use. In our study, both AEL-PC and AEL-PG showed hemolytic activity comparable with that produced by the potent etherlipid, edelfosine. In contrast, no significant hemolysis was observed by the proAEL liposomes, suggesting that the liposomal prodrug strategy could circumvent the traditional side effects of AELs. Indeed, no systemic toxicity was observed when the proAEL liposomes were given to mice even at doses of 1,000 mg/kg mouse body weight. Taken together, these data support the liposomal prodrug delivery concept as a viable strategy for avoiding the hemolytic effects of AELs.

In the sPLA₂-secreting COLO 205 xenograft model, administration of proAEL liposomes resulted in a statistically significant tumor growth delay compared with controls and thus a significant therapeutic effect. No significant body weight loss or systemic toxicities were observed in any of the mice. Although preliminary, these *in vivo* data strongly support the potential of our anticancer strategy and the evasion of hemolysis by the proAEL liposomes. Further studies are required with both non-sPLA₂-secreting xenografts and labeled liposomes to confirm the role of sPLA₂ in the *in vivo* situation and clarify the pharmacokinetics of proAEL liposomal degradation at the tumor target site.

One area of anticancer liposomal technology currently gaining attention is the mode of liposome administration (38). When liposomes are given parenterally via the s.c., i.m., or i.p. routes, they do not access the bloodstream directly but are taken up by the lymphatic capillaries draining the site of administration (e.g., the abdominal and mediastinal lymph nodes) following i.p. administration (38, 39). It has been suggested that minimal lymph node retention occurs of these non-PLA₂-degradable stealth liposomes (8) and that the majority pass into the systemic circulation from the lymph nodes. These observations suggest that our sPLA₂-degradable prodrug liposome strategy has potential for i.p. administration and treatment of lymph node metastases, which are poorly accessible by antitumor agents given i.v. (38).

The sPLA₂ trigger mechanism underlying our strategy suggests that the methodology may also prove successful in the development of several new anticancer lipid-based prodrug agents that selectively target the tumor and are released specifically in the tumor tissue, both issues being essential for future liposome-based drug delivery. For example, antitumor agents such as docosahexanoic acid

(40) or retinoic acids (41) could readily be ester linked to the *sn*-2 position of the prodrug lipid to create double prodrug liposomes, which would allow for tumor-specific release of both AELs and retinoids or DHA. In addition, our system is also applicable as a targeted microcarrier system for delivery of encapsulated compounds that could undergo a tumor-specific sPLA$_2$-mediated release, such as radiation sensitizers, cytokines, immunomodulators, or conventional therapeutics (9). In line with this suggestion, we succeeded recently in producing sPLA$_2$-degradable liposomes containing conventional anticancer drugs such as anthracyclines and platins, which also show promise as being activated by sPLA$_2$ specifically at the tumor site.[4] In all these cases, targeting using our sPLA$_2$-triggered liposomal prodrug delivery system is likely to both decrease toxicity and increase tumor-specific drug delivery resulting in an improvement in therapeutic index. With the technology presented in this work, it would presumably be possible without any prior knowledge of the position, size, and metastatic spread of the tumor to release the chemotherapeutics specifically at the primary and metastatic tumor target sites.

Acknowledgments

References

1. Springer CJ, Niculescu-Duvaz II. Antibody-directed enzyme prodrug therapy (ADEPT). Adv Drug Deliv Rev 1997;26:151–72.

2. Meers P. Enzyme-activated targeting of liposomes. Adv Drug Deliv Rev 2001;53:265–72.

3. Mansour AM, Drevs J, Esser N, et al. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res 2003;63:4062–6.

4. Denmeade SR, Jakobsen CM, Janssen S, et al. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 2003;95:990–1000.

5. DeFeo-Jones D, Brady SF, Feng DM, et al. A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells *in vivo.* Mol Cancer Ther 2002;1:451–9.

6. Kondo M, Asai T, Katanasaka Y, et al. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int J Cancer 2004;108:301–6.

7. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 2000;60:1197–201.

8. Davidsen J, Jørgensen K, Andresen TL, Mouritsen OG. Secreted phospholipase A(2) as a new enzymatic trigger mechanism for localized liposomal drug release and absorption in diseased tissue. Biochim Biophys Acta 2003;1609:95–101.

9. Harrington KJ, Syrigos KN, Vile RG. Liposomally targeted cytotoxic drugs for the treatment of cancer. J Pharm Pharmacol 2002;54: 1573–600.

10. Abe T, Sakamoto K, Kamohara H, Hirano Y, Kuwahara N, Ogawa M.

11. Yamashita S, Yamashita J, Sakamoto K, et al. Increased expression of membrane-associated phospholipase A$_2$ shows malignant potential of human breast cancer cells. Cancer 1993;71:3058–64.

12. Nevalainen TJ, Haapamaki MM, Gronroos JM. Roles of secretory phospholipases A(2) in inflammatory diseases and trauma. Biochim Biophys Acta 2000;1488:83–90.

13. Laye JP, Gill JH. Phospholipase A$_2$ expression in tumors: a target for therapeutic intervention. Drug Discov Today 2003;8:710–6.

14. Jiang J, Neubauer BL, Graff JR, et al. Expression of group IIA secretory phospholipase A$_2$ is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Pathol 2002;160:667–71.

15. Graff JR, Konicek BW, Deddens JA, et al. Expression of group IIA secretory phospholipase A$_2$ increases with prostate tumor grade. Clin Cancer Res 2001;7:3857–61.

16. Leung SY, Chen X, Chu KM, et al. Phospholipase A$_2$ group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc Natl Acad Sci U S A 2002; 99:16203–8.

17. Kiyohara H, Egami H, Kako H, et al. Immunohistochemical localization of group II phospholipase A$_2$ in human pancreatic carcinomas. Int J Pancreatol 1993;13:49–57.

18. Wendum D, Svrcek M, Rigau V, et al. COX-2, inflammatory secreted PLA$_2$, and cytoplasmic PLA$_2$ protein expression in small bowel adenocarcinomas compared with colorectal adenocarcinomas. Mod Pathol 2003;16:130–6.

19. Edhemovic I, Snoj M, Kljun A, Golouh R. Immunohistochemical localization of group II phospholipase A$_2$ in the tumors and mucosa of the colon and rectum. Eur J Oncol 2001;27:545–8.

20. Kennedy BP, Soravia C, Moffat J, et al. Overexpression of the nonpancreatic secretory group II PLA$_2$ messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients. Cancer Res 1998;58:500–3.

21. Chen WM, Soria J, Soria C, Krimsky M, Yedgar S. Control of capillary formation by membrane-anchored extracellular inhibitor of phospholipase A(2). FEBS Lett 2002;522:113–8.

22. Berg OG, Gelb MH, Tsai MD, Jain MK. Interfacial enzymology: the secreted phospholipase A(2)-paradigm. Chem Rev 2001;101:2613–54.

23. Six DA, Dennis EA. The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim Biophys Acta 2000;1488:1–19.

24. Buckland AG, Wilton DC. Anionic phospholipids, interfacial binding and the regulation of cell functions. Biochim Biophys Acta 2000;1483: 199–216.

25. Wieder T, Reutter W, Orfanos CE, Geilen CC. Mechanisms of action of phospholipid analogs as anticancer compounds. Prog Lipid Res 1999; 38:249–59.

26. Berkovic D. Cytotoxic etherphospholipid analogues. Gen Pharmacol 1998;31:511–7.

27. Brachwitz H, Vollgraf C. Analogs of alkyllysophospholipids: chemistry, effects on the molecular level and their consequences for normal and malignant cells. Pharmacol Ther 1995;66:39–82.

28. Lohmeyer M, Bittman R. Antitumor ether lipids and alkylphosphocholines. Drugs Future 1994;19:1021–37.

29. Eue I. Growth inhibition of human mammary carcinoma by liposomal hexadecylphosphocholine: participation of activated macrophages in the antitumor mechanism. Int J Cancer 2001;92:426–33.

30. Ahmad I, Filep JJ, Franklin JC, et al. Enhanced therapeutic effects of liposome-associated 1-*O*-octadecyl-2-*O*-methyl-*sn*-glycero-3-phosphocholine. Cancer Res 1997;57:1915–21.

31. Clive S, Gardiner J, Leonard RC. Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. Cancer Chemother Pharmacol 1999;44:S29–S30.

32. Andresen T, Davidsen J, Begtrup M, Mouritsen O, Jørgensen K. Enzymatic release of antitumor ether lipids by specific phospholipase A$_2$ activation of liposome-forming prodrugs. J Med Chem 2004;47:1694–703.

33. Guivisdalsky P, Bittman R. An efficient stereocontrolled route to both enantiomers of platelet activating factor and analogs with long-chain

---

[4] S.S. Jensen, T.L. Anderson, T. Kaarsgaard, J. Davidsen, T. Fichtner, and K. Jørgensen, unpublished observations.

esters at C-2: saturated and unsaturated ether glycerolipids by opening of glycidyl arenesulfonates. J Org Chem 1989;54:4643–8.

34. Buckland AG, Heeley EL, Wilton DC. Bacterial cell membrane hydrolysis by secreted phospholipases A(2): a major physiological role of human group IIA sPLA(2) involving both bacterial cell wall penetration and interfacial catalysis. Biochim Biophys Acta 2000;1484:195–206.

35. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936–42.

36. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303:1818–22.

37. Lasic DD, Martin F. Stealth liposomes. Florida: CRC Press;1995.

38. Oussoren C, Storm G. Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev 2001;50:143–56.

39. Phillips WT, Medina LA, Klipper R, Goins B. A novel approach for the increased delivery of pharmaceutical agents to peritoneum and associated lymph nodes. J Pharmacol Exp Ther 2002;303:11–6.

40. Siddiqui RA, Jenski LJ, Neff K, Harvey K, Kovacs RJ, Stillwell W. Docosahexaenoic acid induces apoptosis in Jurkat cells by a protein phosphatase-mediated process. Biochim Biophys Acta 2001;1499:265–75.

41. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1:181–93.

Updated version	Access the most recent version of this article at: http://mct.aacrjournals.org/content/3/11/1451	

Cited articles	This article cites 39 articles, 10 of which you can access for free at: http://mct.aacrjournals.org/content/3/11/1451.full#ref-list-1	
Citing articles	This article has been cited by 2 HighWire-hosted articles. Access the articles at: http://mct.aacrjournals.org/content/3/11/1451.full#related-urls	

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.	
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.	
Permissions	To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/3/11/1451. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.	